We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
As Johnson & Johnson (J&J) nears the release of critical phase 3 trial results and potential emergency authorization for its promising COVID-19 vaccine, the company has reportedly hit speedbumps in manufacturing doses. Read More
Eligo said its technology can “precisely modify the composition of the skin’s microbiome to treat or reduce the risk of developing moderate-to-severe acne.” Read More
The Institute for Clinical and Economic Review (ICER) points out seven high-cost treatments whose prices were raised in 2019 without supportive clinical data and cost the U.S. health system $1.2 billion in annual drug spending, in a new analysis released Tuesday. Read More
The vaccine has received a conditional marketing authorization in the EU and is now being administered to high-risk groups in the EU member states. Read More
Pfizer and BioNTech now anticipate manufacturing up to 2 billion doses of their highly effective COVID-19 vaccine by the end of the year as vaccination efforts ramp up and demand for shots increases around the globe. Read More
The European Union has secured 200 million more doses of the Pfizer/BioNTech COVID-19 vaccine, with an option to buy 100 million additional doses, bringing the total number of potential doses contracted for to 600 million. Read More